Showing results (11-20 of 84) with videos related to

Sort By:
Pageof 9
Inflammatory Bowel Diseases|January 12, 2024
Real-world Effectiveness and Safety of Risankizumab in Patients with Moderate to Severe Multirefractory Crohn's Disease: A Belgian Multicentric Cohort StudyDahham Alsoud, João Sabino, Denis Franchimont, et al.
Hepatology (Baltimore, Md.)|April 22, 2006
Differential liver sensitization to toll-like receptor pathways in mice with alcoholic fatty liverThierry Gustot, Arnaud Lemmers, Christophe Moreno, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|August 17, 2022
Predictive models assessing the response to ustekinumab highlight the value of therapeutic drug monitoring in Crohn's diseaseClaire Liefferinckx, Antoine Hubert, Debby Thomas, et al.
Inflammatory Bowel Diseases|January 9, 2007
Multicenter randomized-controlled clinical trial of probiotics (Lactobacillus johnsonii, LA1) on early endoscopic recurrence of Crohn's disease after lleo-caecal resectionAndre Van Gossum, Olivier Dewit, Edouard Louis, et al.
Inflammatory Bowel Diseases|May 13, 2017
Infliximab Trough Levels at Induction to Predict Treatment Failure During MaintenanceClaire Liefferinckx, Charlotte Minsart, Jean-François Toubeau, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|January 5, 2002
Gene profiling reveals unknown enhancing and suppressive actions of glucocorticoids on immune cellsJerome Galon, Denis Franchimont, Naoki Hiroi, et al.
Acta Gastro-Enterologica Belgica|November 23, 2011
The genetics of familial adenomatous polyposis (FAP) and MutYH-associated polyposis (MAP)Kathleen Claes, Karin Dahan, S Tejpar, et al.
Patient Preference and Adherence|July 18, 2018
Preference for a prefilled syringe or an auto-injection device for delivering golimumab in patients with moderate-to-severe ulcerative colitis: a randomized crossover studySéverine Vermeire, François D'heygere, Antoine Nakad, et al.
European Journal of Gastroenterology & Hepatology|January 24, 2019
Early vedolizumab trough levels at induction in inflammatory bowel disease patients with treatment failure during maintenanceClaire Liefferinckx, Charlotte Minsart, Anneline Cremer, et al.
Pharmacogenetics and Genomics|September 27, 2006
The TNF/ADAM 17 system: implication of an ADAM 17 haplotype in the clinical response to infliximab in Crohn's diseaseVinciane Dideberg, Emilie Théâtre, Frédéric Farnir, et al.
Pageof 9